/ Anktiva
Why Is ImmunityBio (IBRX) Rallying Today? EU Approves Anktiva
ImmunityBio stock surged more than 20% after the European Commission granted conditional approval for its bladder cancer treatment, Anktiva.
February 18, 2026Amid Biotech Pitfalls, this Stock Has Outperformed NVDA in the Last 3 Months
In the last three months, this biotech stock outperformed Nvidia (NVDA) by over 3x.
May 13, 2024